Literature DB >> 35015881

New life for an old therapy: ELTD1 as a downstream target of angiogenesis.

Deanna Marie Tiek1, Shi-Yuan Cheng1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35015881      PMCID： PMC8917398          DOI： 10.1093/neuonc/noab286

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

Review 1.  VEGF as a key mediator of angiogenesis in cancer.

Authors:  Peter Carmeliet
Journal:  Oncology       Date:  2005-11-21       Impact factor: 2.935

Review 2.  Anti-VEGF therapies in the clinic.

Authors:  Kellen L Meadows; Herbert I Hurwitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 3.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

4.  Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization.

Authors:  Lothar C Dieterich; Sofie Mellberg; Elise Langenkamp; Lei Zhang; Agata Zieba; Henriikka Salomäki; Martin Teichert; Hua Huang; Per-Henrik Edqvist; Theo Kraus; Hellmut G Augustin; Tommie Olofsson; Erik Larsson; Ola Söderberg; Grietje Molema; Fredrik Pontén; Patrik Georgii-Hemming; Irina Alafuzoff; Anna Dimberg
Journal:  J Pathol       Date:  2012-08-31       Impact factor: 7.996

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.

Authors:  Ken Chang; Biqi Zhang; Xiaotao Guo; Min Zong; Rifaquat Rahman; David Sanchez; Nicolette Winder; David A Reardon; Binsheng Zhao; Patrick Y Wen; Raymond Y Huang
Journal:  Neuro Oncol       Date:  2016-05-04       Impact factor: 12.300

Review 7.  Current FDA-Approved Therapies for High-Grade Malignant Gliomas.

Authors:  Jacob P Fisher; David C Adamson
Journal:  Biomedicines       Date:  2021-03-22

8.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

9.  Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.

Authors:  Michelle Zalles; Nataliya Smith; Jadith Ziegler; Debra Saunders; Shannon Remerowski; Lincy Thomas; Rafal Gulej; Nadya Mamedova; Megan Lerner; Kar-Ming Fung; Junho Chung; Kyusang Hwang; Junyeong Jin; Graham Wiley; Chase Brown; James Battiste; Jonathan D Wren; Rheal A Towner
Journal:  J Cell Mol Med       Date:  2019-12-21       Impact factor: 5.310

10.  ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.

Authors:  Hua Huang; Maria Georganaki; Lei Liu Conze; Bàrbara Laviña; Luuk van Hooren; Kalyani Vemuri; Tiarne van de Walle; Mohanraj Ramachandran; Lei Zhang; Fredrik Pontén; Michael Bergqvist; Anja Smits; Christer Betsholtz; Elisabetta Dejana; Peetra U Magnusson; Liqun He; Roberta Lugano; Anna Dimberg
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 12.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.